Condition

Clinical trials for Type 2 Diabetes Mellitus (T2DM)

Active public studies that list Type 2 Diabetes Mellitus (T2DM) as a condition.

29active studies

15recruiting now

21countries represented

70largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 1

Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity

Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)Condition

MWN105 1, MWN105 2Treatment

China1 locations

Shanghai Minwei Biotechnology Co., LtdSponsor

Updated 2026-09-08 · NCT07803809See eligibility →

Recruiting nowPhase 2

Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)Condition

MWN109 1, MWN109 2Treatment

China1 locations

Shanghai Minwei Biotechnology Co., LtdSponsor

Updated 2026-09-03 · NCT07801820See eligibility →

Recruiting nowPhase 1

A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors

Healthy Participants, ObesityCondition

Placebo, ACI-19764 at dose A1Treatment

Netherlands1 locations

AC Immune SASponsor

Updated 2026-09-02 · NCT07463196See eligibility →

Recruiting nowPhase 3

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

Obesity, OverweightCondition

Enicepatide, PlaceboTreatment

China18 locations

Hoffmann-La RocheSponsor

Updated 2026-08-13 · NCT07670416See eligibility →

Recruiting nowNot applicable

Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy

Type 2 Diabetes Mellitus (T2DM), Obesity (Disorder)Condition

NutriSteppe Digital Dietary InterventionTreatment

Kazakhstan1 locations

Kazakh Academy of NutritionSponsor

Updated 2026-08-11 · NCT07728669See eligibility →

Recruiting nowNot applicable

The Transit Bipartition With the Use of a Metallic Anastomosis Clip and Circular Fundocorporeal Gastroplication

Type 2 Diabetes Mellitus (T2DM), Obesity & OverweightCondition

Laparoscopic transit bipartition with Metallic Anastomotic Clip and Circular Fundocorporeal Gastroplication, Laparoscopic transit bipartition (gastroenteroanastomosis and entero-enteric anastomosis) use the Metallic Anastomotic Clip and with sleeve gastrectomyTreatment

Kazakhstan1 locations

The Society of Bariatric and Metabolic Surgeons of KazakhstanSponsor

Updated 2026-05-07 · NCT07495020See eligibility →

Recruiting nowPhase 4

Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM)Condition

Oral semaglutide, Empagliflozin 10 mgTreatment

Slovenia1 locations

University Medical Centre LjubljanaSponsor

Updated 2026-04-30 · NCT06613854See eligibility →

Recruiting nowPhase 4

The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM), SemaglutideCondition

semaglutide, caloric restrictionTreatment

China1 locations

Second Affiliated Hospital of Nanchang UniversitySponsor

Updated 2026-04-02 · NCT07272343See eligibility →

Recruiting nowNot applicable

Targeted Precision Nutrition Strategy To Prevent Chronic Metabolic Diseases

Obesity and Overweight, Pre-diabeticCondition

Optimal Metabotype-specific diet, Sub-optimal dietTreatment

Netherlands2 locations

Maastricht University Medical CenterSponsor

Updated 2026-01-20 · NCT06923644See eligibility →

Recruiting nowNot applicable

WeArable teChnology daTa driVen digitAl healTh cOachINg (ACTIVATION)- A Mixed-methods Study

Elevated Blood Pressure, HypertensionCondition

Smart watch, Dashboard with nudging systemTreatment

Singapore1 locations

Alexandra HospitalSponsor

Updated 2025-10-02 · NCT06752772See eligibility →

Recruiting nowPhase 2

Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes

Type 2 Diabetes Mellitus (T2DM), Food EffectCondition

MKP10241, PlaceboTreatment

Australia1 locations

Mankind Pharma LimitedSponsor

Updated 2025-09-29 · NCT07098663See eligibility →

Recruiting nowNot applicable

Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.

Cardiovascular Diseases, Metabolic SyndromeCondition

Blood WorkTreatment

United States1 locations

Clindove Research LLCSponsor

Updated 2025-08-12 · NCT07106879See eligibility →

Recruiting nowNot applicable

Cardiovascular Risk in Children With Chronic Conditions Study

Kidney Transplant, Familial HypercholesterolaemiaCondition

Intervention not listedTreatment

Hungary3 locations

Semmelweis UniversitySponsor

Updated 2025-08-08 · NCT07086989See eligibility →

Recruiting nowPhase 3

A Study of BGM0504 in Participants with Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM)Condition

Drug: 5 mg BGM0504 Administered SC, Drug:10 mg BGM0504 Administered SCTreatment

China1 locations

BrightGene Bio-Medical Technology Co., Ltd.Sponsor

Updated 2025-02-07 · NCT06716216See eligibility →

Recruiting nowNot applicable

Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2

Type 2 Diabetes Mellitus (T2DM), Type 2 DiabetesCondition

Intervention not listedTreatment

Japan1 locations

Osaka Metropolitan UniversitySponsor

Updated 2024-12-04 · NCT06694012See eligibility →

Opening soonPhase 2

HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide

Type 2 Diabetes Mellitus (T2DM), SarcopeniaCondition

Calcium-HMB Plus Vitamin D3, Matching placeboTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-08-28 · NCT07760948See eligibility →

Opening soonNot applicable

Evaluation of Neuregulin-4 (NRG4) Levels in Obese and Non-Obese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes MellitusCondition

Intervention not listedTreatment

Turkey (Türkiye)1 locations

GÜLDEN ANATACASponsor

Updated 2026-07-29 · NCT07734558See eligibility →

Opening soonNot applicable

Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide

Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes MelitusCondition

Mazdutide(Dual GLP-1R/GCGR Agonist), Semaglutide (1 Mg Dose)Treatment

Locations pending0 locations

Tianjin Medical UniversitySponsor

Updated 2026-07-20 · NCT07713992See eligibility →

Opening soonPhase 3

BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM)Condition

Bofanglutide, SemaglutideTreatment

Mexico7 locations

Carnot LaboratoriesSponsor

Updated 2026-06-05 · NCT07628985See eligibility →

Opening soonNot applicable

CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

Psoriatic Arthritis, OsteoarthitisCondition

TirzepatideTreatment

Mexico1 locations

JULIO GRANADOS MONTIELSponsor

Updated 2026-05-12 · NCT07567378See eligibility →

Opening soonPhase 2

Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)Condition

PG-102, PlaceboTreatment

Australia1 locations

ProGen. Co., Ltd.Sponsor

Updated 2025-09-23 · NCT07187856See eligibility →

Opening soonPhase 3

Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus

Obesity, Type 2 Diabetes Mellitus (T2DM)Condition

Semaglutide PenTreatment

Bangladesh1 locations

Popular Medical College HospitalSponsor

Updated 2024-09-27 · NCT06616961See eligibility →

Invitation onlyNot applicable

To Test the Effectiveness and Implementation Approach of a 3-month PILI Pasifika Program Lifestyle Program With Components of Social Determinants of Health Activities in Real-world Settings (Clinical and Non-clinical Settings) Across 3 Years

Cardiometabolic Conditions, Hypertension (HTN)Condition

PILI (Partnership for Improving Lifestyle Intervention) Pasifika ProgramTreatment

United States2 locations

University of HawaiiSponsor

Updated 2026-06-09 · NCT07387393See eligibility →

Active, not recruitingPhase 1, Phase 2

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)Condition

ALN-4324, PlaceboTreatment

Argentina, Canada22 locations

Alnylam PharmaceuticalsSponsor

Updated 2026-08-14 · NCT06845202See eligibility →

Active, not recruitingPhase 2

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)Condition

Placebo, EnicepatideTreatment

Argentina, Canada70 locations

Carmot Therapeutics, Inc.Sponsor

Updated 2026-06-24 · NCT06628362See eligibility →

Active, not recruitingNot applicable

Eating Window and Sleep Disorders on Glycemic Control, Cardiovascular Risk, and Weight Loss

Type 2 Diabetes Mellitus (T2DM), HypertensionCondition

Comparison of eating windows interventionTreatment

Brazil1 locations

Federal University of São PauloSponsor

Updated 2026-04-24 · NCT06735859See eligibility →

Active, not recruitingNot applicable

MRI Assessment of Pancreatic Fat Changes and Islet Function Recovery After Bariatric Surgery in Obese Patients

Obesity & Overweight, Type 2 Diabetes Mellitus (T2DM)Condition

Laparoscopic Sleeve Gastrectomy (LSG)Treatment

China1 locations

yu li，MDSponsor

Updated 2026-03-12 · NCT07464223See eligibility →

Active, not recruitingPhase 3

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)Condition

GZR18, semaglutideTreatment

China1 locations

Gan & Lee Pharmaceuticals.Sponsor

Updated 2025-11-25 · NCT06778967See eligibility →

Active, not recruitingPhase 2

Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes MellitusCondition

PG-102, PlaceboTreatment

South Korea14 locations

ProGen. Co., Ltd.Sponsor

Updated 2025-07-11 · NCT06712615See eligibility →

Related conditions

Obesity1,102 Obesity & Overweight220 Overweight205 Overweight and Obesity130 Type 2 Diabetes108 Hypertension107

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.